Report Materials
DVA Laboratory Services, Inc. (DVA), did not always comply with Medicare requirements for tests billed with an AY modifier for beneficiaries with end-stage renal disease (ESRD). Specifically, for 62 of the 100 beneficiary-days, DVA submitted separate claims using the AY modifier for tests furnished for the treatment of ESRD contrary to the consolidated billing requirement. In addition, DVA did not always comply with other Medicare requirements. These errors occurred primarily because DVA did not have adequate controls to comply with certain Medicare requirements. On the basis of our sample results, we estimated that Medicare overpaid DVA at least $989,000 for tests that were furnished for the treatment of ESRD.
Furthermore, for 21 of the 100 beneficiary-days, we did not have enough evidence to make a determination whether Medicare appropriately paid DVA an estimated $469,000 for tests billed with an AY modifier or not ordered by a physician.
Notice
This report may be subject to section 5274 of the National Defense Authorization Act Fiscal Year 2023, 117 Pub. L. 263.